CA2371524A1 - Craving reduction method and toothpick delivery system for active e.g. nicotine - Google Patents
Craving reduction method and toothpick delivery system for active e.g. nicotine Download PDFInfo
- Publication number
- CA2371524A1 CA2371524A1 CA 2371524 CA2371524A CA2371524A1 CA 2371524 A1 CA2371524 A1 CA 2371524A1 CA 2371524 CA2371524 CA 2371524 CA 2371524 A CA2371524 A CA 2371524A CA 2371524 A1 CA2371524 A1 CA 2371524A1
- Authority
- CA
- Canada
- Prior art keywords
- nicotine
- stage
- delivery system
- craving
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
SPECIFICATION:
This invention relates to an oral delivery system for an active in the form of a manually manipulated toothpick. It is common in devices such as this to have a flavor agent added for chewing appeal; it is of course not necessary but superficially appealing. This flavor additive has no other effect pharmacologically.
Other means by which a pharmacologically active may be delivered (e.g. gum) do not always appeal to every individual and the manually dexterous actions common in the activity of smoking are not addressed.
However the manipulation of a toothpick closely mimic that of smoking, thereby appealing more to those so use to, perhaps one could even say addicted to, those actions. Also the packaging system may resemble that of historically typical cigarette packaging, with toothpicks inserted into a foam block at the bottom of the packaging. Flavor additives may also mimic cigarette types (e.g. U. S. or Canadian types) as well as the more traditional mint and cinnamon varieties.
PICTURES: Fig 1 TOOTHPICK
CLAIMS: Show all claims *** Note: Data on abstracts and claims is shown in the official language in which it was submitted.
This invention relates to an oral delivery system for an active in the form of a manually manipulated toothpick. It is common in devices such as this to have a flavor agent added for chewing appeal; it is of course not necessary but superficially appealing. This flavor additive has no other effect pharmacologically.
Other means by which a pharmacologically active may be delivered (e.g. gum) do not always appeal to every individual and the manually dexterous actions common in the activity of smoking are not addressed.
However the manipulation of a toothpick closely mimic that of smoking, thereby appealing more to those so use to, perhaps one could even say addicted to, those actions. Also the packaging system may resemble that of historically typical cigarette packaging, with toothpicks inserted into a foam block at the bottom of the packaging. Flavor additives may also mimic cigarette types (e.g. U. S. or Canadian types) as well as the more traditional mint and cinnamon varieties.
PICTURES: Fig 1 TOOTHPICK
CLAIMS: Show all claims *** Note: Data on abstracts and claims is shown in the official language in which it was submitted.
Claims
CLAIMS:
The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:"
23. A method of substituting harmful and unpleasant behavior with a less detrimental and less socially unacceptable behavior.
24. A delivery system (e.g. for nicotine that controls tobacco cravings), comprising: an orally manipulatable wood base material; and active intermixed with said wood base material, said active, upon oral manipulation of the toothpick base material by a user for therewith causing release of a dose of active achieving a rapid transmucosally absorbable pharmacological effect (e.g.
reducing tobacco craving.) 25. The system of Claim 24, wherein said dose releases between 0.01 and O.l milligrams of nicotine within.
minutes of commencing chewing.
26. A two-stage active delivery system, comprising: a toothpick, means cooperating with said toothpick for providing an initial dose of a medicine capable of achieving a rapid transmucosally absorbable pharmacological effect upon oral manipulation of said toothpick and a second dose of said medicine capable of achieving a prolonged transmucosally absorbable pharmacological effect upon subsequent reversing of said toothpick.
27. The two-stage medicine delivery system of claim 26, wherein said initial and second doses are separate forms of said medicine.
28. The two-stage medicine delivery system of claim 26, wherein the medicine is nicotine.
29. The two-stage medicine delivery system of claim 26, wherein said medicine is nicotine or other active.
30. The two-stage medicine delivery system of claim 27, wherein one of said doses is a nicotine salt and the other of said doses is nicotine polacrilex.
31. The two-stage medicine delivery system of claim 27, wherein said initial dose releases between 0.01 and 0.1 milligrams of nicotine within 5 minutes of having been placed in a user's mouth.
32. The two-stage medicine delivery system of claim 31, wherein said means second dose maintains, for at least 20 minutes a prolonged concentration of active in the user's blood which is at least as high as the active concentration achieved in the user's blood by the initial dose.
33. The two-stage medicine delivery system of claim 32, wherein said initial nicotine concentration is at least 0.01 nanograms of nicotine per milliliter of blood.
34. The two-stage medicine delivery system of claim 33, wherein the prolonged concentration of nicotine is at least 0.05 nanogram of nicotine per milliliter of blood.
35. The two-stage medicine delivery system of claim 32, wherein said medicine is a craving counteracting substance, and said rapid and prolonged therapeutic effects include a rapid and prolonged reduction of a craving.
36. A two-stage nicotine delivering product for use in counteracting cravings for nicotine-containing tobacco products, comprising: a wood base; a nicotine compound mixed with the base so that oral actuation of the base causes the nicotine compound to be released into a user's mouth for transmucosal absorption within the first 5 minutes after oral actuation begins; and a nicotine maintenance compound mixed with the base so that oral actuation of the base causes the nicotine maintenance compound to be released into the user's mouth for prolonged transmucosal absorption which lasts at least 20 minutes beyond said first five minutes.
37. The two-stage nicotine delivering product of claim 36, wherein said nicotine loading compound is 0.01 to 0.1 milligrams of a nicotine salt.
38. The two-stage nicotine delivering product of claim 37, wherein said nicotine salt is nicotine tartrate.
39. The two-stage nicotine delivering product of claim 36, wherein said nicotine maintenance compound is .1 to .4 milligrams of nicotine in an ion exchange resin gum.
40. The two-stage nicotine delivering product of claim 39, wherein said nicotine in an ion exchange resin gum is nicotine polacrilex.
41. The two-stage nicotine delivering product of claim 36, wherein said nicotine maintenance compound is .1 to .4 milligrams of encapsulated nicotine salt.
42. The two-stage nicotine delivering product of claim 36, wherein said nicotine maintenance compound is adapted to maintain, for said at least 20 minutes, a prolonged concentration of nicotine in the user's blood which is at least as high as a loaded nicotine concentration achieved in the user's blood by said nicotine loading compound.
43. The two-stage nicotine delivering product of claim 42, wherein said loaded nicotine concentration is at least .2 nanograms of nicotine per milliliter of blood.
44. The two-stage nicotine delivering product of claim 43, wherein said prolonged concentration of nicotine is at least 1 nanogram of nicotine per milliliter of blood.
45. A method of making a medicine delivery system which reduces a craving when orally retained, said method comprising the steps of providing a base material which is adapted to be retained in a user's mouth;
mixing a loading compound into the base material so that said loading compound remains releasable and rapidly transmucosally absorbable to counteract said craving within 5 minutes after the base material is orally retained; and mixing a maintenance compound into the base material so that said maintenance compound remains releasable and transmucosally absorbable over a prolonged period of time to counteract said craving for at least 20 minutes after oral retention of the base material begins.
46. The method of claim 45, wherein said craving is a nicotine craving and said loading compound is 0.2 to 0.7 milligrams of nicotine salt.
47. The method of claim 45, wherein said craving is a nicotine craving and said maintenance compound is 1 to 4 grams of nicotine in an ion exchange resin gum.
48. The method of claim 47. wherein said 1 to 4 grams of nicotine in an ion exchange resin gum is nicotine polacrilex.
49. The method of claim 47, wherein said craving is a nicotine craving and said maintenance compound is encapsulated nicotine salt.
50. A graduated amount of active increasing in concentration from a minimal at each end of said toothpick to a maximum at the middle achieving results in an individually tailored dose depending upon tenacity of chewing.
51. A method to achieve claim 50, comprising an initial complete soak of wood base material in active and a secondary partial soak in a neutral (e.g. water).
The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:"
23. A method of substituting harmful and unpleasant behavior with a less detrimental and less socially unacceptable behavior.
24. A delivery system (e.g. for nicotine that controls tobacco cravings), comprising: an orally manipulatable wood base material; and active intermixed with said wood base material, said active, upon oral manipulation of the toothpick base material by a user for therewith causing release of a dose of active achieving a rapid transmucosally absorbable pharmacological effect (e.g.
reducing tobacco craving.) 25. The system of Claim 24, wherein said dose releases between 0.01 and O.l milligrams of nicotine within.
minutes of commencing chewing.
26. A two-stage active delivery system, comprising: a toothpick, means cooperating with said toothpick for providing an initial dose of a medicine capable of achieving a rapid transmucosally absorbable pharmacological effect upon oral manipulation of said toothpick and a second dose of said medicine capable of achieving a prolonged transmucosally absorbable pharmacological effect upon subsequent reversing of said toothpick.
27. The two-stage medicine delivery system of claim 26, wherein said initial and second doses are separate forms of said medicine.
28. The two-stage medicine delivery system of claim 26, wherein the medicine is nicotine.
29. The two-stage medicine delivery system of claim 26, wherein said medicine is nicotine or other active.
30. The two-stage medicine delivery system of claim 27, wherein one of said doses is a nicotine salt and the other of said doses is nicotine polacrilex.
31. The two-stage medicine delivery system of claim 27, wherein said initial dose releases between 0.01 and 0.1 milligrams of nicotine within 5 minutes of having been placed in a user's mouth.
32. The two-stage medicine delivery system of claim 31, wherein said means second dose maintains, for at least 20 minutes a prolonged concentration of active in the user's blood which is at least as high as the active concentration achieved in the user's blood by the initial dose.
33. The two-stage medicine delivery system of claim 32, wherein said initial nicotine concentration is at least 0.01 nanograms of nicotine per milliliter of blood.
34. The two-stage medicine delivery system of claim 33, wherein the prolonged concentration of nicotine is at least 0.05 nanogram of nicotine per milliliter of blood.
35. The two-stage medicine delivery system of claim 32, wherein said medicine is a craving counteracting substance, and said rapid and prolonged therapeutic effects include a rapid and prolonged reduction of a craving.
36. A two-stage nicotine delivering product for use in counteracting cravings for nicotine-containing tobacco products, comprising: a wood base; a nicotine compound mixed with the base so that oral actuation of the base causes the nicotine compound to be released into a user's mouth for transmucosal absorption within the first 5 minutes after oral actuation begins; and a nicotine maintenance compound mixed with the base so that oral actuation of the base causes the nicotine maintenance compound to be released into the user's mouth for prolonged transmucosal absorption which lasts at least 20 minutes beyond said first five minutes.
37. The two-stage nicotine delivering product of claim 36, wherein said nicotine loading compound is 0.01 to 0.1 milligrams of a nicotine salt.
38. The two-stage nicotine delivering product of claim 37, wherein said nicotine salt is nicotine tartrate.
39. The two-stage nicotine delivering product of claim 36, wherein said nicotine maintenance compound is .1 to .4 milligrams of nicotine in an ion exchange resin gum.
40. The two-stage nicotine delivering product of claim 39, wherein said nicotine in an ion exchange resin gum is nicotine polacrilex.
41. The two-stage nicotine delivering product of claim 36, wherein said nicotine maintenance compound is .1 to .4 milligrams of encapsulated nicotine salt.
42. The two-stage nicotine delivering product of claim 36, wherein said nicotine maintenance compound is adapted to maintain, for said at least 20 minutes, a prolonged concentration of nicotine in the user's blood which is at least as high as a loaded nicotine concentration achieved in the user's blood by said nicotine loading compound.
43. The two-stage nicotine delivering product of claim 42, wherein said loaded nicotine concentration is at least .2 nanograms of nicotine per milliliter of blood.
44. The two-stage nicotine delivering product of claim 43, wherein said prolonged concentration of nicotine is at least 1 nanogram of nicotine per milliliter of blood.
45. A method of making a medicine delivery system which reduces a craving when orally retained, said method comprising the steps of providing a base material which is adapted to be retained in a user's mouth;
mixing a loading compound into the base material so that said loading compound remains releasable and rapidly transmucosally absorbable to counteract said craving within 5 minutes after the base material is orally retained; and mixing a maintenance compound into the base material so that said maintenance compound remains releasable and transmucosally absorbable over a prolonged period of time to counteract said craving for at least 20 minutes after oral retention of the base material begins.
46. The method of claim 45, wherein said craving is a nicotine craving and said loading compound is 0.2 to 0.7 milligrams of nicotine salt.
47. The method of claim 45, wherein said craving is a nicotine craving and said maintenance compound is 1 to 4 grams of nicotine in an ion exchange resin gum.
48. The method of claim 47. wherein said 1 to 4 grams of nicotine in an ion exchange resin gum is nicotine polacrilex.
49. The method of claim 47, wherein said craving is a nicotine craving and said maintenance compound is encapsulated nicotine salt.
50. A graduated amount of active increasing in concentration from a minimal at each end of said toothpick to a maximum at the middle achieving results in an individually tailored dose depending upon tenacity of chewing.
51. A method to achieve claim 50, comprising an initial complete soak of wood base material in active and a secondary partial soak in a neutral (e.g. water).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2371524 CA2371524A1 (en) | 2002-02-07 | 2002-02-07 | Craving reduction method and toothpick delivery system for active e.g. nicotine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2371524 CA2371524A1 (en) | 2002-02-07 | 2002-02-07 | Craving reduction method and toothpick delivery system for active e.g. nicotine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2371524A1 true CA2371524A1 (en) | 2003-08-07 |
Family
ID=27626640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2371524 Abandoned CA2371524A1 (en) | 2002-02-07 | 2002-02-07 | Craving reduction method and toothpick delivery system for active e.g. nicotine |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2371524A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2423757A (en) * | 2005-03-05 | 2006-09-06 | Boots Co Plc | Packet of nicotine-containing elements |
| CN109030398A (en) * | 2018-08-28 | 2018-12-18 | 中国烟草总公司郑州烟草研究院 | A kind of buccal cigarette nicotine release behavior detection method and its special test equipment |
-
2002
- 2002-02-07 CA CA 2371524 patent/CA2371524A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2423757A (en) * | 2005-03-05 | 2006-09-06 | Boots Co Plc | Packet of nicotine-containing elements |
| CN109030398A (en) * | 2018-08-28 | 2018-12-18 | 中国烟草总公司郑州烟草研究院 | A kind of buccal cigarette nicotine release behavior detection method and its special test equipment |
| CN109030398B (en) * | 2018-08-28 | 2024-05-17 | 中国烟草总公司郑州烟草研究院 | Method for detecting nicotine release behavior of buccal cigarettes and special test instrument thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6248760B1 (en) | Tablet giving rapid release of nicotine for transmucosal administration | |
| US6583160B2 (en) | Nicotine therapy method and oral carrier for assuaging tobacco-addiction | |
| RU2008149508A (en) | COATED PHARMACEUTICAL PRODUCT FOR DELIVERY OF NICOTINE TO THE ORAL CAVITY, INCLUDING TROMETAMOL AS GIVING AGENT BUFFER PROPERTIES | |
| US5783207A (en) | Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine | |
| US20080166395A1 (en) | Article for delivering substrates to the oral cavity | |
| RU2003137595A (en) | COATED GUM, CONTAINING NICOTINE, METHOD FOR PRODUCING IT AND ITS USE | |
| US20010016593A1 (en) | Element giving rapid release of nicotine for transmucosal administration | |
| EP2536301B1 (en) | Oral smokeless tobacco products and oral smokeless non-tobacco snuff products comprising carbamide or carbamide salts | |
| CA2549642A1 (en) | Effervescent oral opiate dosage forms and methods of administering opiates | |
| ATE411008T1 (en) | LONG-LASTING, FLAVORED DOSAGE FORM FOR PROLONGED RELEASE OF ACTIVE SUBSTANCES IN THE MOUTH | |
| EP3065578A1 (en) | Oral smokeless tobacco products and oral smokeless non-tobacco snuff products | |
| US20050034738A1 (en) | Chewing tobacco substitute containing nicotine | |
| CA2346330A1 (en) | Medicated chewing gum delivery system for nicotine | |
| US8968770B2 (en) | Multi-part kit comprising a chewing gum and further a flavor containing formulation | |
| KR102038342B1 (en) | Nicotine formulation | |
| US20040002520A1 (en) | Composition and method for cessation of Nicotine cravings | |
| US6645470B1 (en) | Treatment and system for nicotine withdrawal | |
| JPH06315367A (en) | Smoking prohibiting instrument | |
| US20060112965A1 (en) | Chewing tobacco substitute containing cotinine | |
| CA2371524A1 (en) | Craving reduction method and toothpick delivery system for active e.g. nicotine | |
| US20100256197A1 (en) | Nicotine Dissolving Film With Or Without Menthol | |
| US20080017205A1 (en) | Method and Device for Releasing Flavor and Odor Substances | |
| US20030082109A1 (en) | Dextrorotary nicotine for smoking cessation | |
| KR20010068314A (en) | The Antismoking Aid containing an Artemisia | |
| Bassey-Duke | Nicotine and its effects on periodontal tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |